Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHASM CS randomized trial in cardiac sarcoidosis
jRCTs011210048Active, not recruiting
- Sponsor
- Canadian Institutes of Health Research
- Start
- Nov 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Randomised, open-label trial of prednisone, methotrexate and folic acid in cardiac sarcoidosis (CS) (2 arms), sponsored by Canadian Institutes of Health Research. Primary endpoint: Summed perfusion rest score on FDG-PET scan. Started Nov 2021; status: active, not recruiting.
02
Drugs
prednisonemethotrexatefolic acid
03
Conditions
cardiac sarcoidosis (CS)
Beyond the preview
Go deeper on jRCTs011210048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs011210048.